CD19-CAR T-cell therapy induces deep tissue depletion of B cells
Authors' conclusion
This study demonstrates complete B-cell depletion in secondary lymphoid tissues of patients with AIDs following CD19-CAR T-cell therapy combined with standard lymphodepleting therapy.
Study context
- Population
- Patients with autoimmune diseases (AIDs)plus 3 with non-lymphoid organ biopsies
- Comparison
- CD19-CAR T-cell therapy vs rituximab (RTX) treatment
- CD19-CAR Tn = five
- RTXn = fivereference
- Outcome
- Lymph node tissue after treatment
Methodological detailssequential ultrasound-guided inguinal lymph node biopsies, comparison with RTX-treated patients
- Sequential ultrasound-guided inguinal lymph node biopsies
- Comparison with RTX-treated patients
Main finding
As reported in the abstract
- CD19+ and CD20+ B cells completely depleted in lymph nodes after CD19-CAR T-cell therapy, but not after RTX
- Plasma cells, T cells and macrophages in lymph nodes unchanged
- Follicular structures disrupted and follicular dendritic cells (FDCs) depleted after CD19-CAR T-cell therapy, but not after RTX
Further findings
Non-lymphoid organ biopsies (colon, kidney, gallbladder) after CD19-CAR T-cell therapy
- Non-lymphoid organs completely depleted of B cells
- Three additional patients with AID
Original publication
CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Ann Rheum Dis. Published 2 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →